Loading stock data…
AptarGroup (ATR)
$125.41-0.58 (-0.46%)
Market OpenUpdated 3:09 PM EDT
AptarGroup, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AptarGroup, Inc. in the Healthcare sector is trading at $125.38 with a market capitalization of $7.6B. Wall Street consensus targets $160.43 (7 analysts), implying a +28.0% move over the next 12 months. The stock is currently 24% below its 52-week high of $164.28, remaining 0.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $982.87M↑ | $962.74M↑ | $961.13M↓ | $966.01M↑ | $887.30M |
| Gross Profit | $351.91M↑ | $338.22M↓ | $363.08M↓ | $367.01M↑ | $336.41M |
| Operating Income | $108.58M↓ | $110.32M↓ | $139.09M↓ | $145.97M↑ | $115.49M |
| Net Income | $72.67M↓ | $74.34M↓ | $127.93M↑ | $111.72M↑ | $78.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and bever...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.51%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.70%
Volume
Today's trading volume
182,755
Recent News
Is West Pharmaceutical Stock Outperforming the S&P 500?
West Pharmaceutical continues to outpace broader market gains on strong earnings momentum and supportive analyst sentiment.
A Look At AptarGroup (ATR) Valuation After Recent Share Price Weakness
AptarGroup (ATR) has drawn investor attention after a recent price slide, with the stock down about 6% over the past month and about 15% in the past 3 months from its last close of US$113.36. See our latest analysis for AptarGroup. The recent 1 day share price gain of 0.72% sits against a softer backdrop, with the 30 day share price return down 6.31% and the 1 year total shareholder return down 24.99%, which points to fading momentum despite a slightly positive 3 year total shareholder return...
Greif Rewards Shareholders With 10.7% Hike in Quarterly Dividend
GEF boosts its quarterly dividend 10.7%, supported by stronger free cash flow, lower leverage and a commitment to returning capital.
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results. President and Chief Executive Officer Stephan Tanda told shareholders that he p
AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.